1) Hematologic Malignancies expanded to include any T-cell Malignancy (previously B-cell only).
2) The B-cell Malignancy enrollment of the dose escalation phase is now closed
3) Mount Sinai Medical Center in New York has been added as a 9th site.
The addition of a new center with a dedicated immunotherapy program is definitely a positive. Joshua Brody, MD, who's speciality is lymphoma immunotherapy will be the primary investigator. I doubt a new center would be added if preliminary results were not looking promising.
Significance of expansion to T-cell malignancies is uncertain. T-cell lymphomas are only about 15% of lymphomas so would be harder to enroll and likely why these were not included initially. My guess is that with the possible success being seen in B-cell malignancies it was elected to include the T-cell malignancies at this point.
1) The addition of another site is likely more a function of the Mount Sinai investigators wanting to offer an exciting new therapy to their patients than it is Celldex wanting to increase recruitment.
2) Expansion of scope from B-cell malignancies to include T-cell malignancies is in my opinion an attempt to include other hematologic malignancies in this new therapeutic option.
Remember that there have already been several impressive responses in B-cell malignancies including: "one ongoing complete response in an aggressively pretreated patient with Hodgkins disease, now with a progression free survival of nearly nine months "(this was as of Nov 2013; I hope this patient is still experiencing a complete response).
Why depressing, weight? Do you have a lot bought on margin or something? If not, then I would consider this anything but depressing. You can get a stock with all that CLDX has in its favor (just look at some of Long's recent posts, and others if you need a reminder).... and, you can buy it at $11 a share. Think how much you could afford to buy at $38. You can now buy 3.5x that many shares. How is that even depressing?